▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #289 by analyst upside · 2026-09-09
SPRY
ARS Pharmaceuticals, Inc.
Healthcare · Market Cap $536M · P/E 0x
ANALYST PRICE TARGET
+317.4%
implied upside to consensus target
Current Price $5.39
Consensus Target $22.5
Bull Target $30.0
Bear Target $15.0
Analysts Covering 4
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
4
Hold
0
Sell
0
52-Week Low $4.91
52-Week High $13.15
YTD Return -53.1%
FUNDAMENTALS
Market Cap $536M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-2.18
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $117M
Profit Margin -184.2%
52-WEEK RANGE
52-Week Low $4.91
52-Week High $13.15
Current Price $5.39
Bear Target $15.0
Bull Target $30.0
● Now $5.39 ● Target $22.5
TRADING DATA
Avg Volume 2.0M
YTD Return -53.1%
Analyst Count 4
Consensus Buy
Upside to Target +317.4%
Last Updated 2026-09-09

ANALYST SUMMARY

ARS Pharmaceuticals, Inc. (SPRY) is currently trading at $5.39 with a Wall Street consensus price target of $22.5, implying potential upside of 317.4% over the next 12 months. 4 analysts currently cover SPRY, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $30.0, while the most cautious has a target of $15.0.

SPRY operates in the Healthcare sector with a market capitalisation of $536M. The stock is down 53.1% year-to-date and is currently trading near the lower end of its 52-week range of $4.91 – $13.15.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

PALI +364.6%
Palisade Bio, Inc.
$383M · P/E 3.4x · Buy
QTTB +250.7%
Q32 Bio Inc.
$348M · P/E 3.7x · Buy
XFOR +231.0%
X4 Pharmaceuticals, Inc.
$348M · P/E 2.5x · Buy
PLX +315.1%
Protalix BioTherapeutics, Inc.
$214M · P/E 11.5x · Buy
SABS +220.6%
SAB Biotherapeutics, Inc.
$330M · P/E 15.1x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for SPRY, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Leerink Partners - Reiterated
Outperform → Outperform 2026-06-25 29% win rate (7 calls)
Cantor Fitzgerald - Reiterated
Overweight → Overweight 2026-05-28 40% win rate (10 calls)
Roth Capital ● Initiated
Buy 2025-09-04 Building track record
Scotiabank ● Initiated
Sector Outperform 2025-03-07 20% win rate (5 calls)
Raymond James - Reiterated
Strong Buy → Strong Buy 2025-01-14 Building track record
Leerink Partners - Reiterated
Outperform → Outperform 2025-01-13 29% win rate (7 calls)
Cantor Fitzgerald reit
Overweight → Overweight 2024-10-08 40% win rate (10 calls)
Leerink Partners - Reiterated
Outperform → Outperform 2024-09-20 29% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
39
out of 100
Coverage depth
12/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →